Accreditation Council for Medical Affairs Begins Board Certification Program for Biologics and Biosimilars
Shots:
- The ACMA is launching a board-certified biologic and biosimilars specialist program (BCBBS), the first accredited program specializing in biologics & biosimilars
- The BCBBS program is a self-paced & the first and only US and international board certification program for health care professionals & researchers. The focus is to establish expertise among professionals involved in the optimization of biological therapy
- The certification covers a variety of topics incl. the history of biologics, FDA resources, the Purple Book, regulatory & economic considerations, clinical guidelines, real-world evidence, and the future outlook on biosimilars. The program consists of 8 modules completed over 6mos. for an avg. of 40hrs.
Ref: PR Newswire | Image: ACMA
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
